Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

Sharmila Raghunandan; Cassandra D. Josephson; Hans Verkerke; W. Matthew Linam; Treva C. Ingram; Patricia E. Zerra; Connie M. Arthur; Sean R. Stowell; Michael Briones; Satheesh Chonat

doi:10.3389/fped.2020.616731

Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

Sharmila Raghunandan
, Cassandra D. Josephson
, Hans Verkerke
, W. Matthew Linam
, Treva C. Ingram
, Patricia E. Zerra
, Connie M. Arthur
, Sean R. Stowell
, Michael Briones
, Satheesh Chonat

Research output: Contribution to journal › Article › peer-review

Abstract

Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.

Original language	English (US)
Article number	616731
Journal	Frontiers in Pediatrics
Volume	8
DOIs	https://doi.org/10.3389/fped.2020.616731
State	Published - Dec 29 2020
Externally published	Yes

Keywords

COVID - 19
SARS-CoV-2
acute respiratory distress syndrome (ARDS)
children
complement
eculizumab
pediatric

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.3389/fped.2020.616731

Cite this

@article{d3784f36657d4d6fbfda638dc71e8287,

title = "Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome",

abstract = "Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.",

keywords = "COVID - 19, SARS-CoV-2, acute respiratory distress syndrome (ARDS), children, complement, eculizumab, pediatric",

author = "Sharmila Raghunandan and Josephson, \{Cassandra D.\} and Hans Verkerke and Linam, \{W. Matthew\} and Ingram, \{Treva C.\} and Zerra, \{Patricia E.\} and Arthur, \{Connie M.\} and Stowell, \{Sean R.\} and Michael Briones and Satheesh Chonat",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Raghunandan, Josephson, Verkerke, Linam, Ingram, Zerra, Arthur, Stowell, Briones and Chonat.",

year = "2020",

month = dec,

day = "29",

doi = "10.3389/fped.2020.616731",

language = "English (US)",

volume = "8",

journal = "Frontiers in Pediatrics",

issn = "2296-2360",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

AU - Raghunandan, Sharmila

AU - Josephson, Cassandra D.

AU - Verkerke, Hans

AU - Linam, W. Matthew

AU - Ingram, Treva C.

AU - Zerra, Patricia E.

AU - Arthur, Connie M.

AU - Stowell, Sean R.

AU - Briones, Michael

AU - Chonat, Satheesh

PY - 2020/12/29

Y1 - 2020/12/29

N2 - Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.

AB - Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.

KW - COVID - 19

KW - SARS-CoV-2

KW - acute respiratory distress syndrome (ARDS)

KW - children

KW - complement

KW - eculizumab

KW - pediatric

UR - https://www.scopus.com/pages/publications/85099309580

UR - https://www.scopus.com/pages/publications/85099309580#tab=citedBy

U2 - 10.3389/fped.2020.616731

DO - 10.3389/fped.2020.616731

M3 - Article

AN - SCOPUS:85099309580

SN - 2296-2360

VL - 8

JO - Frontiers in Pediatrics

JF - Frontiers in Pediatrics

M1 - 616731

ER -

Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this